Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UYSC vs ABVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UYSC Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–1 Matrix Metrics)

UYSC Overall Winner 6-Pillar Tally: UYSC 3 – 1 ABVX (2 Tie) Matrix Metrics: UYSC 7 – 1 ABVX

As of Nov 20, 2026, UYSC (UYSC) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UYSC carries a Unified Composite Score of 51.5/100 (HOLD) at $11.04 (N/M Forward P/E, 0.0% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin).

  • Technical & Structure Timing Caution: UYSC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 83.3); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UYSC vs ABVX
UYSC US Equity Head-to-Head Winner
UYSC
Institutional Equity
$11.04
+0.0% 1D
Market Cap $84.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.01β · 7% Vol
Unified Composite Score
51.5 / 100 HOLD
Tech 45.0 Fund 47.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 83
RSI-14: 83.3 · SMA20: $10.39 · SMA50: $10.33
ABVX NASDAQ
Abivax SA American Depositary Shares
Pharmaceutical Preparations
$73.20
-9.24% 1D
Market Cap $7.1B
TTM Revenue $4.7M
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 25.0 Fund 38.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 30
RSI-14: 30.0 · SMA20: $86.08 · SMA50: $91.16

6-Pillar Scorecard Institutional Category Breakdown (UYSC 3 – 1 ABVX)

Columns: Metric · UYSC · ABVX
1. Valuation Multiples UYSC
Forward P/E N/M N/M
Trailing P/E 35.5x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABVX
Revenue Growth (YoY) +0.0% -6.8%
Earnings Growth (YoY) -30.0% +0.0%
TTM Revenue (USD) N/A $4.7M
Market Cap $84.2M $7.1B
3. Profitability & Quality UYSC
Gross Margin N/A 100.0%
Operating Margin 0.0% -6270.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 38.2% -252.3%
4. Balance Sheet & Cash Flow UYSC
Cash Generation (TTM) N/A -$292M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage 38.2% ROE $5.16 Book/Sh · -252.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 76.9% (<1st %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Shell Companies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UYSC (7) vs ABVX (1)
Institutional Metric UYSC ABVX Criterion Row Edge
Market Capitalization
Scale
$84.2M $7.1B Larger Scale ABVX
Trailing P/E Ratio
Valuation
35.5x N/M Lower Multiple UYSC
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -6.8% Higher Growth UYSC
Operating Margin (TTM)
Profitability
0.0% -6270.4% Higher Margin UYSC
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
38.2% -252.3% Higher ROE UYSC
52-Week Range Position
Momentum
62% ($10–$12) 12% ($63–$149) Stronger Trend UYSC
Beta / 30D Volatility
Risk Regime
-0.01β · 7% Vol 1.55β · 55% Vol Lower Realized Risk UYSC
Unified Institutional Score
Composite Signal
51.5 / 100 (HOLD) 42.4 / 100 (HOLD) Higher Composite UYSC
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (38.2% ROE) -$292M EBITDA ($5.16 Book/Sh · -252.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UYSC +33.81 pp
UYSC: +3.18% · ABVX: -30.63%
3M Horizon UYSC +25.89 pp
UYSC: +7.18% · ABVX: -18.71%
6M Horizon UYSC +28.45 pp
UYSC: +8.13% · ABVX: -20.32%
1Y Horizon UYSC +28.45 pp
UYSC: +8.13% · ABVX: -20.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UYSC vs ABVX. Trailing 12-month operating profitability (UYSC 0.0% vs ABVX -6270.4%) and valuation multiples (UYSC N/M vs ABVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UYSC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E38.2% · N/M
ABVX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.7M
Gross Margin100.0%
Op. Margin-6270.4%
ROE / Fwd P/E-252.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UYSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UYSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UYSC Moat Profile High-Margin Pricing Power Moat
Shell Companies Operator
Competes within the Shell Companies value chain with $84.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.1B market capitalization and -6270.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UYSC vs ABVX Key Questions & Quantitative Answers

As of Nov 20, 2026, UYSC (UYSC) is the stronger overall head-to-head candidate over Abivax SA (ABVX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UYSC carries a Unified Composite Score of 51.5/100 (HOLD) at $11.04 (N/M Forward P/E, 0.0% operating margin), whereas ABVX carries 42.4/100 (HOLD) at $73.20 (N/M Forward P/E, -6270.4% operating margin). Technical & Structure Timing Caution: UYSC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 83.3); meanwhile ABVX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVX leads the Growth & Scale pillar: UYSC posts +0.0% YoY revenue growth and -30.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABVX at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $4.7M TTM revenue (100.0% gross margin, -6270.4% operating margin). On trailing 12-month operating scale, UYSC generates N/A in USD-normalized revenue versus $4.7M for ABVX. In operating R&D and SG&A reinvestment, UYSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVX.

UYSC screens cheaper on headline valuation multiples. UYSC trades at N/M Forward P/E, 35.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UYSC (38.2% ROE) versus ABVX (-252.3% ROE) capital efficiency.

In options market volatility and institutional positioning, UYSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.01β · 7% Vol realized risk). By comparison, ABVX carries 76.9% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.